About: Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection
Creator	Bouzid, Donia Casalino, Enrique Descamps, Diane Houhou-Fidouh, Nadhira Lescure, François-Xavier Timsit, Jean-François Visseaux, Benoit Yazdanpanah, Yazdan Collin, Gilles Lucet, Jean-Christophe Bouadma, Lila Le Hingrat, Quentin Deconinck, Laurène Le Pluart, Diane Lebourgeois, Samuel
Source	Medline; PMC
abstract	In the race to contain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), efficient detection and triage of infected patients must rely on rapid and reliable testing. In this work, we performed the first evaluation of the QIAstat-Dx respiratory SARS-CoV-2 panel (QIAstat-SARS) for SARS-CoV-2 detection. This assay is the first rapid multiplex PCR (mPCR) assay, including SARS-CoV-2 detection, and is fully compatible with a non-PCR-trained laboratory or point-of-care (PoC) testing. This evaluation was performed using 69 primary clinical samples (66 nasopharyngeal swabs [NPS], 1 bronchoalveolar lavage fluid sample [BAL], 1 tracheal aspirate sample, and 1 bronchial aspirate sample) comparing SARS-CoV-2 detection with the currently WHO-recommended reverse transcription-PCR (RT-PCR) (WHO-RT-PCR) workflow. Additionally, a comparative limit of detection (LoD) assessment was performed for QIAstat-SARS and WHO-RT-PCR using a quantified clinical sample. Compatibility of sample pretreatment for viral neutralization or viscous samples with the QIAstat-SARS system were also tested. The QIAstat-Dx respiratory SARS-CoV-2 panel demonstrated a sensitivity comparable to that of the WHO-recommended assay with a limit of detection at 1,000 copies/ml. The overall percent agreement between QIAstat-Dx SARS and WHO-RT-PCR on 69 clinical samples was 97% with a sensitivity of 100% (40/40) and specificity at 93% (27/29). No cross-reaction was encountered for any other respiratory viruses or bacteria included in the panel. The QIAstat-SARS rapid multiplex PCR panel provides a highly sensitive, robust, and accurate assay for rapid detection of SARS-CoV-2. This assay allows rapid decisions even in non-PCR-trained laboratory or point-of-care testing, allowing innovative organization.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1128/jcm.00630-20
bibo:pmid	32341142
has license	cc-by
sha1sum (hex)	78fc5e1e2ae4a9f489c71d4eec190bebc61a5b47
schema:url	https://doi.org/10.1128/jcm.00630-20
resource representing a document's title	Evaluation of the QIAstat-Dx Respiratory SARS-CoV-2 Panel, the First Rapid Multiplex PCR Commercial Assay for SARS-CoV-2 Detection
has PubMed Central identifier	PMC7383528
has PubMed identifier	32341142
schema:publication	J Clin Microbiol
resource representing a document's body	covid:78fc5e1e2ae4a9f489c71d4eec190bebc61a5b47#body_text
is schema:about of	named entity 'aspirate' named entity 'copies' named entity 'sample' named entity 'robust' named entity 'multiplex PCR' named entity 'rapid' named entity 'encountered' named entity 'MULTIPLEX PCR' named entity 'ROBUST' named entity 'DECISIONS' named entity 'WORKFLOW' named entity 'TESTING' named entity 'OVERALL' named entity 'NEUTRALIZATION' named entity 'ACCURATE' named entity 'BRONCHOALVEOLAR LAVAGE FLUID SAMPLE' covid:arg/78fc5e1e2ae4a9f489c71d4eec190bebc61a5b47 named entity 'point-of-care testing' named entity 'limit' named entity 'assay' named entity 'assay' named entity 'sample' named entity 'detection' named entity 'The' named entity 'NPS' named entity 'rapid' named entity 'highly' named entity 'sample' named entity 'This' named entity 'detection' named entity 'performed' named entity 'assessment' named entity 'detection' named entity 'PoC' named entity 'comparative' named entity 'detection' named entity 'efficient' named entity 'rapid' named entity 'race' named entity 'Respiratory' named entity 'bronchoalveolar lavage fluid' named entity 'SARS' named entity 'reverse transcription' named entity 'PCR' named entity '40/40' named entity 'Multiplex PCR' named entity 'PCR' named entity 'RT-PCR' named entity 'laboratory testing' named entity 'synthetic DNA' named entity 'point-of-care' named entity 'Paris' named entity 'PCR' named entity 'SARS-CoV-2' named entity 'Cobas' named entity 'virus' named entity 'B virus' named entity 'sensitivity and specificity' named entity 'genetic material' named entity 'bacteria' named entity 'microorganisms' named entity 'PCR' named entity 'standard curve' named entity 'gene' named entity 'viruses' named entity 'teaching hospital' named entity 'multiplex PCR'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software